By Mill Chart
Last update: May 26, 2025
SANOFI-ADR (NASDAQ:SNY) stands out as an attractive candidate for value investors, according to our fundamental screening. The company combines reasonable valuation with strong profitability and a solid dividend, making it worth a closer look.
SNY appears undervalued based on key metrics:
These figures indicate the stock is priced conservatively relative to its earnings potential.
The company excels in profitability, with several standout metrics:
While SNY maintains a solid balance sheet, there are minor concerns:
For a deeper dive, review the full fundamental analysis of SNY.
Our Decent Value Stocks screener lists more stocks with similar characteristics and is updated regularly.
This is not investing advice! The article highlights observations at the time of writing, but you should conduct your own analysis before making investment decisions.
NASDAQ:SNY (5/28/2025, 10:02:42 AM)
52.27
-0.12 (-0.23%)
Find more stocks in the Stock Screener
SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors.